Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies

Journal of Gastrointestinal Surgery

Volumn 12, Issue 2, 2008, Pages 288-296

  Holcomb, Bryan ^a   Yip Schneider, Michele T ^a   Matos, Jesus M ^a   Dixon, Jennifer ^a   Kennard, Jason ^a   Mahomed, Julie ^a   Shanmugam, Rajasubramaniam ^a   Sebolt Leopold, Judith ^d   Schmidt, C Max ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d PFIZER INC   (United States)

Author keywords

Gemcitabine; MAP kinase; NF B; Pancreatic cancer; PI3 kinas

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CHROMONE DERIVATIVE; CURCUMIN; DEOXYCYTIDINE; DRUG DERIVATIVE; ENZYME INHIBITOR; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MORPHOLINE DERIVATIVE; PROTEIN KINASE B;

ADENOCARCINOMA; ARTICLE; CELL CULTURE; CELL PROLIFERATION; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; GEL MOBILITY SHIFT ASSAY; GENETICS; HUMAN; PANCREAS TUMOR; PHYSIOLOGY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMONES; CURCUMIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME INHIBITORS; HUMANS; MAP KINASE SIGNALING SYSTEM; MORPHOLINES; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR CELLS, CULTURED;

EID: 47749086343     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-007-0406-6     Document Type: Article

References (24)

1. Society AC. Cancer Facts & Figures 2005. Paper presented at: American Cancer Society, Atlanta, 2005.
2. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221(6):721-731. discussion 731-723.
3. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4(6):567-579.
4. Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduo-denectomy: a 20-year experience in 516 patients. Arch Surg 2004;139(7):718-725. discussion 725-717.
5. Goldstein D, Carroll S, Apte M, Keogh G. Modern management of pancreatic carcinoma. Intern Med J 2004;34(8): 475-481.
6. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15(6):2403-2413.
7. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005;446(5):475-482.
8. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific,signal-induced phosphorylation. Science 1995;267(5203):1485-1488.
9. Lin YC, Brown K, Siebenlist U. Activation of NF-kappa B requires proteolysis of the inhibitor I kappa B-alpha: signal-induced phosphorylation of I kappa B-alpha alone does not release active NF-kappa B. Proc Natl Acad Sci U S A 1995;92 (2):552-556.
10. Arlt A, Vorndamm J, Breitenbroich M, et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 2001;20 (7):859-868.
11. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and Akt/ PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22(21): 3243-3251.
12. Muerkoster S, Arlt A, Witt M, et al. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003;104(4):469-476.
13. Martelli AM, Faenza I, Billi AM, et al. Intranuclear 3′-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal 2006;18(8):1101-1107.
14. Altomare DA, Tanno S, De Rienzo A, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2003;88(1):470-476.
15. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000;60 (19):5451-5455.
16. Yokoi K, Fidler IJ. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004;10(7):2299-2306.
17. Viala E, Pouyssegur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann N Y Acad Sci 2004;1030:208-218.
18. Zhao Y, Shen S, Guo J, et al. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J Surg Res 2006;136(2):325-335.
19. Sawai H, Funahashi H, Okada Y, et al. Interleukin-1alpha enhances IL-8 secretion through p38 mitogen-activated protein kinase and reactive oxygen species signaling in human pancreatic cancer cells. Med Sci Monit 2005;11(10):BR343-BR350.
20. Chandler NM, Canete JJ, Callery MP. Increased expression of NF-kappa B subunits in human pancreatic cancer cells. J Surg Res 2004;118(1):9-14.
21. Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther 2005;4 (4):587-594.
22. Duvoix A, Blasius R, Delhalle S, et al. Chemo preventive and therapeutic effects of cur cumin. Cancer Lett 2005;223(2): 181-190.
23. Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS, Muscarella P. A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg 2006;10 (2):207-214.
24. Shah SA, Potter MW, Hedeshian MH, Kim RD, Chari RS, Callery MP. PI-3′ kinase and NF-kappaB cross-signaling in human pancreatic cancer cells. J Gastrointest Surg 2001;5(6):603-612. discussion 612-603.